Media Releases

Montréal, Canada, January 13, 2026 — mylife Diabetes Care and CamDiab are pleased to announce that Health Canada has approved the use of myLoop powered by CamAPS FX app with both iOS and Abbott’s FreeStyle Libre 3 Plus sensor.* The approval expands system compatibility, offering greater choice for people living with type 1 diabetes. 

myLoop combines the YpsoPump insulin pump with the CamAPS FX app and algorithm, developed by CamDiab Ltd, and compatible continuous glucose monitoring systems. By integrating adaptive, smartphone-based automated insulin delivery (AID), myLoop is designed to simplify diabetes management, reduce the burden of ongoing therapy-related decision-making, and support greater personal freedom and flexibility in everyday life.  

Building on momentum in Canada 

Less than a year after its launch in Canada, approval of both iOS and the FreeStyle Libre 3 Plus sensor reflects the continued collaboration between mylife Diabetes Care, CamDiab and Abbott in response to patient and healthcare professional needs. 

Launched in March 2025 on Android, myLoop was the first smartphone-based automated insulin delivery system on the Canadian market and has since seen growing adoption among people living with type 1 diabetes and healthcare professionals. 

 “For people living with type 1 diabetes, daily therapy involves countless decisions. Expanding myLoop compatibility reduces that burden and gives people greater confidence and freedom in how they manage their diabetes—every day,” said Karina Schneider, general manager of Ypsomed Canada.  

Reducing the mental burden of diabetes 

Managing type 1 diabetes involves numerous health-related decisions, including glucose monitoring, insulin dosing, nutrition and activity planning.i In Europe, where myLoop has been available for more than three years, patient-reported experience data highlights its impact on daily life. In the dQ&A surveyii, users rated myLoop number one for reducing the perceived mental load associated with diabetes management. 

Commercial availability is subject to launch timing and local market conditions. 

About mylife Diabetes Care 

mylife Diabetes Care is a global diabetes care company based in Switzerland, dedicated to improving the lives of people living with diabetes by empowering them to gain more freedom through better control. The company is fully focused on modern automated insulin delivery (AID) solutions designed for people living with diabetes, enabled through close collaboration with healthcare professionals and payers worldwide. For more information, visit www.mylife-diabetescare.com 

Media Contact  Catherine Perreault 1-833-695-5959, catherine.perreault@mylife-diabetescare.com  

About CamDiab 

CamDiab Ltd is a digital health and personalized medicine company focused on the design, development, and commercialization of its world leading, interoperable CamAPS FX hybrid closed-loop app. CamAPS FX is designed to use an adaptive, self-learning control algorithm, linked to a compatible continuous glucose monitoring device and a compatible insulin pump, to autonomously compute and direct insulin delivery to maintain tight glycaemic control. Since its founding in 2019, its mission has been to help people with type 1 diabetes and their families live better lives. Find out more at www.camdiab.com. 

Media contact Martin Ashcroft, media@camdiab.com